The compounds of the invention are represented by the following general structure
##STR1##
or a pharmaceutically acceptable salt thereof, and compositions containing them,
wherein the variables are defined herein, and their use to reduce or inhibit PTH
secretion, including methods for reducing or inhibiting PTH secretion and methods
for treatment or prophylaxis of diseases associated with bone disorders, such as
osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism.
The subject invention also relates to processes for making such compounds as well
as to intermediates useful in such processes.
